←Cancer
Study register · detail Cancer · 1975

The analgesic properties of delta-9-tetrahydrocannabinol and codeine.

Noyes et al.
No direction reported
Sample—
Summary

Clinical study with oral THC (single dose) in patients with cancer pain: THC showed a mild analgesic effect. 20 mg THC caused treatment-limiting side effects (somnolence, dizziness, ataxia, visual disturbances) and in some cases alarming reactions; 10 mg was well tolerated and was analgesically effective despite its sedative effect. Caveat: very small, old single-dose study, narrow therapeutic window.

Authors
Noyes R, Brunk SF, Avery DA, Canter AC.
DOI 10.1002/cpt197518184↗
Share
Abstract
The administration of single oral doses of delta-9-tetrahydrocannabinol (THC) to patients with cancer pain demonstrated a mild analgesic effect. At a dose of 20 mg, however, THC induced side effects that would prohibit its therapeutic use including somnolence, dizziness, ataxia, and blurred vision. Alarming adverse reactions were also observed at this dose. THC, 10 mg, was well tolerated and, despite its sedative effect, may analgesic potential.
Indication
Further studies on Cancer
All studies →
S Hauser et al. · 2023 · The Cochrane database of systematic reviews
53 citations
Cannabis-based medicines and medical cannabis for adults with cancer pain.
No benefit demonstrated Meta-Analyse

Cochrane SR, k=14 RCTs (n=1.823), Cannabis-basierte Medikamente vs. Placebo bei moderaten bis schweren Krebsschmerzen trotz Opioid-Therapie. Moderate Evidenz: Nabiximols/THC keine klinisch relevante Wirksamkeit; PGIC-Verbesserung RD=0,06 (95%-KI 0,01–0,12; NNTB=16); Schmerzintensität SMD=-0,19 (95%-KI -0,40 bis 0,02). Niedrige Evidenz: CBD kein Zusatznutzen gegenüber Palliativversorgung allein (1 Studie, n=144). Fazit: Moderate Evidenz für Unwirksamkeit oraler/oromukosaler Cannabinoide bei opioid-refraktären Krebsschmerzen.

10.1002/14651858.cd014915.pub2 View study →
S Herman et al. · 1979 · The New England Journal of Medicine
216 citations
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.
Clear benefit Randomized Controlled Trial (double-blind crossover)

n=113 Krebspatienten unter Chemotherapie (Doppelblind-Crossover-RCT, NEJM 1979); Ansprechrate Nabilon 80% vs. Prochlorperazin 32% (p<0,001); Übelkeit (p<0,01) und Erbrechen (p<0,001) jeweils signifikant seltener unter Nabilon; Patienten bevorzugten Nabilon zur Fortführung (p<0,001).

10.1056/nejm197906073002302 View study →
S Whiting et al. · 2015 · JAMA
2103 citations
Cannabinoids for Medical Use
Mixed

Umfassende SR über 79 RCTs (n=6.462) zu medizinischem Cannabis; moderate Evidenz für Chemotherapie-induzierte Übelkeit/Erbrechen (CINV), schwache Evidenz für Appetit-Stimulation bei HIV/Krebs-Kachexie; Nabilon/Dronabinol überlegen vs. Placebo (OR=3.82 für CINV-Kontrolle, 95%-KI 1.55–9.42).

10.1001/jama.2015.6358 View study →

The impediment to action advances action. — Marcus Aurelius